{"organizations": [], "uuid": "79a6399b2f74bc1a438cbeb5aee7cb405582d7aa", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-neovacs-announces-positive-data-re/brief-neovacs-announces-positive-data-review-from-last-idsmb-review-prior-to-final-results-of-phase-iib-clinical-trial-of-ifnalpha-kinoid-in-lupus-idUSFWN1Q3010", "country": "US", "domain_rank": 408, "title": "Neovacs Announces Positive Data Review From Last IDSMB Review Prior To Final Results Of Phase IIb Clinical Trial Of Ifnalpha Kinoid In Lupus", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.943, "site_type": "news", "published": "2018-02-13T14:24:00.000+02:00", "replies_count": 0, "uuid": "79a6399b2f74bc1a438cbeb5aee7cb405582d7aa"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-neovacs-announces-positive-data-re/brief-neovacs-announces-positive-data-review-from-last-idsmb-review-prior-to-final-results-of-phase-iib-clinical-trial-of-ifnalpha-kinoid-in-lupus-idUSFWN1Q3010", "ord_in_thread": 0, "title": "Neovacs Announces Positive Data Review From Last IDSMB Review Prior To Final Results Of Phase IIb Clinical Trial Of Ifnalpha Kinoid In Lupus", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - Neovacs Sa:\n* REG-NEOVACS ANNOUNCES POSITIVE DATA REVIEW FROM LAST IDSMB REVIEW PRIOR TO FINAL RESULTS OF PHASE IIB CLINICAL TRIAL OF IFNALPHA KINOID IN LUPUS\n* NEOVACS SA - FINAL TRIAL RESULTS EXPECTED IN JUNE 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T14:24:00.000+02:00", "crawled": "2018-02-14T12:27:20.002+02:00", "highlightTitle": ""}